Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)- methylenedioxymethamphetamine

Toxicological Sciences

Volumn 143, Issue 1, 2015, Pages 209-219

  Lizarraga, Lucina E ^a   Cholanians, Aram B ^a   Phan, Andy V ^a   Herndon, Joseph M ^a   Lau, Serrine S ^a   Monks, Terrence J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Hyperactivity; Hyperthermia; MDMA; Neurotoxicity; Ro4 1284; VMAT2

Indexed keywords

2 ETHYL 1,2,3,4,6,7 HEXAHYDRO 2 HYDROXY 3 ISOBUTYL 9,10 DIMETHOXY 11BH BENZO[A]QUINOLIZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; BRAIN MONOAMINE; INDOLEAMINE; SEROTONIN; VESICULAR MONOAMINE TRANSPORTER 2; MIDOMAFETAMINE; PSYCHEDELIC AGENT; SLC18A2 PROTEIN, RAT; VESICULAR MONOAMINE TRANSPORTER;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BODY TEMPERATURE; BRAIN CORTEX; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; EXPLORATORY BEHAVIOR; HYPERACTIVITY; HYPERTHERMIA; LOCOMOTION; LONG TERM CARE; MALE; MONOAMINE RELEASE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PROTEIN DEPLETION; RAT; REARING; STAINING; THERMOGENESIS; THERMOREGULATION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEVER; HYPERKINESIS; METABOLISM; MOTOR ACTIVITY; NEUROTOXICITY SYNDROMES; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; SEROTONINERGIC NERVE CELL; SPRAGUE DAWLEY RAT; TIME FACTOR;

RATTUS;

2H-BENZO(A)QUINOLIZIN-2-OL, 2-ETHYL-1,3,4,6,7,11B-HEXAHYDRO-3-ISOBUTYL-9,10-DIMETHOXY-; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE REGULATION; BRAIN; DISEASE MODELS, ANIMAL; FEVER; HALLUCINOGENS; HYPERKINESIS; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; RATS, SPRAGUE-DAWLEY; SEROTONERGIC NEURONS; SEROTONIN; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84928679175     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu222     Document Type: Article

References (63)

1. Aguirre, N., Barrionuevo, M., Lasheras, B., and Del Rio, J. (1998). The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. J. Pharmacol. Exp. Ther. 286, 1159-1165.
2. Aguirre, N., Barrionuevo, M., Ramirez, M., Del Rio, J., and Lasheras, B. (1999). Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 10, 3675-80.
3. Ball, K. T., Budreau, D., and Rebec, G. V. (2003). Acute effects of 3,4-methylenedioxymethamphetamine on striatal singleunit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res.994, 203-215.
4. Baumann, M. H., Clark, R. D., Budzynski, A. G., Partilla, J. S., Blough, B. E., and Rothman, R. B. (2005). N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30, 550-560.
5. Beckmann, J. S., Denehy, E. D., Zheng, G., Crooks, P. A., Dwoskin, L. P., and Bardo, M. T. (2012). The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology (Berl) 220, 395-403.
6. Beckmann, J. S., Siripurapu, K. B., Nickell, J. R., Horton, D. B., Denehy, E. D., Vartak, A., Crooks, P. A., Dwoskin, L. P., and Bardo, M. T. (2010). The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 335, 841-851.
7. Bernstein, A. I., Stout, K. A., and Miller, G. W. (2014). The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem. Int. 73, 89-97.
8. Breier, J. M., Bankson, M. G., and Yamamoto, B. K. (2006). Ltyrosine contributes to ({thorn})-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J. Neurosci. 26, 290-299.
9. Brodie, B. B., Hess, S. M., and Shore, P. A. (1956). Persistence of reserpine action after the disappearance of drug from brain: effect on serotonin. J. Pharmacol. Exp. Ther. 118, 84-89.
10. Bubar, M. J., Pack, K. M., Frankel, P. S., and Cunningham, K. A. (2004). Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of ({thorn})-MDMA. Psychopharmacology (Berl) 173, 326-336.
11. Callaway, C. W., Wing, L. L., and Geyer, M. A. (1990). Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Exp.Ther. 254, 456-464.
12. Capela, J. P., Carmo, H., Remiao, F., Bastos, M. L., Meisel, A., and Carvalho, F. (2009). Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 39, 210-271.
13. Capela, J. P., Lautenschlager, M., Dirnagl, U., Bastos, M. L., Carvalho, F., and Meisel, A. (2008). 5,7-Dihydroxitryptamine toxicity to serotonergic neurons in serum free raphe cultures. Eur. J. Pharmacol. 588, 232-238.
14. Chen, J. J., Ondo, W. G., Dashtipour, K., and Swope, D. M. (2012). Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin. Ther. 34, 1487-1504.
15. Eyerman, D. J., and Yamamoto, B. K. (2005). Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther. 312, 160-169.
16. Fisher, A., Biggs, C. S., Eradiri, O., and Starr, M. S. (2000). Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent. Neuroscience 95, 97-111.
17. Fitzgerald, J. L., and Reid, J. J. (1993). Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn. Schmiedebergs.Arch. Pharmacol. 347, 313-323.
18. Fukui, M., Rodriguiz, R. M., Zhou, J., Jiang, S. X., Phillips, L. E., Caron, M. G., and Wetsel, W. C. (2007). Vmat2 heterozygous mutant mice display a depressive-like phenotype. J. Neurosci.27, 10520-10529.
19. Fumagalli, F., Gainetdinov, R. R., Wang, Y. M., Valenzano, K. J., Miller, G. W., and Caron, M. G. (1999). Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-outmice. J. Neurosci. 19, 2424-2431.
20. Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E., and Colado, M. I. (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55, 463-508.
21. Gu, X. F., and Azmitia, E. C. (1993). Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur. J. Pharmacol. 235, 51-57.
22. Gudelsky, G. A., and Nash, J. F. (1996). Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem.66, 243-249.
23. Guillot, T. S., and Miller, G. W. (2009). Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149-170.
24. Guillot, T. S., Shepherd, K. R., Richardson, J. R., Wang, M. Z., Li, Y., Emson, P. C., and Miller, G. W. (2008). Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J. Neurochem. 106, 2205-2217.
25. Hekmatpanah, C. R., McKenna, D. J., and Peroutka, S. J. (1989). Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. Neurosci. Lett.104, 178-182.
26. Kanthasamy, A., Sprague, J. E., Shotwell, J. R., and Nichols, D. E. (2002). Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 114, 917-924.
27. Liu, H.-F., Lu, S., Ho, P. W.-L., Tse, H.-M., Pang, S. Y.-Y., Kung, M.H.-W., Ho, J. W.-M., Ramsden, D. B., Zhou, Z.-J., and Ho, S.-L. (2014). LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity. Ann. Clin. Transl. Neurol. 1, 199-208.
28. Lizarraga, L. E., Phan, A. V., Cholanians, A. B., Herndon, J. M., Lau, S. S., and Monks, T. J. (2014). Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(6)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats. Toxicol. Sci. 139, 421-431.
29. Marston, H. M., Reid, M. E., Lawrence, J. A., Olverman, H. J., and Butcher, S. P. (1999). Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology (Berl) 144, 67-76.
30. Mechan, A. O., Esteban, B., O'Shea, E., Elliott, J. M., Colado, M. I., and Green, A. R. (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 135, 170-180.
31. Meyer, A. C., Neugebauer, N. M., Zheng, G., Crooks, P. A., Dwoskin, L. P., and Bardo, M. T. (2013). Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J. Neurochem. 127, 187-198.
32. Nickell, J. R., Siripurapu, K. B., Vartak, A., Crooks, P. A., and Dwoskin, L. P. (2014). The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv. Pharmacol. 69, 71-106.
33. O'Shea, E., Granados, R., Esteban, B., Colado, M. I., and Green, A.R. (1998). The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37, 919-926.
34. Parsons, S. M. (2000). Transport mechanisms in acetylcholine and monoamine storage. FASEB J. 14, 2423.
35. Partilla, J. S., Dempsey, A. G., Nagpal, A. S., Blough, B. E., Baumann, M. H., and Rothman, R. B. (2006). Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 319, 237-246.
36. Partilla, J. S., Dersch, C. M., Yu, H., Rice, K. C., and Rothman, R. B. (2000). Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (-)-HY038. Brain Res. Bull. 53, 821-826.
37. Pearson, S. J., and Reynolds, G. P. (1988). Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 27, 717-719.
38. Pettibone, D. J., Totaro, J. A., and Pflueger, A. B. (1984). Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol. 102, 425-430.
39. Pothos, E. N., Larsen, K. E., Krantz, D. E., Liu, Y., Haycock, J.W., Setlik, W., Gershon, M. D., Edwards, R. H., and Sulzer, D. (2000). Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20, 7297-7306.
40. Reveron, M. E., Monks, T. J., and Duvauchelle, C. L. (2005). Age-dependent ({thorn})MDMA-mediated neurotoxicity in mice. Neurotoxicology 26, 1031-1040.
41. Ricaurte, G. A., Yuan, J., and McCann, U. D. (2000). (6)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42, 5-10.
42. Riddle, E. L., Topham, M. K., Haycock, J. W., Hanson, G. R., and Fleckenstein, A. E. (2002). Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449, 71-74.
43. Rothman, R. B., and Baumann, M. H. (2002). Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol.Ther. 95, 73-88.
44. Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., and Partilla, J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
45. Rudnick, G., and Clark, J. (1993). From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim. Biophys. Acta 1144, 249-263.
46. Sabol, K. E., Lew, R., Richards, J. B., Vosmer, G. L., and Seiden, L. S. (1996). Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J. Pharmacol. Exp. Ther. 276, 846-854.
47. Sabol, K. E., and Seiden, L. S. (1998). Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res. 806, 69-78.
48. Sanchez, V., Camarero, J., Esteban, B., Peter, M. J., Green, A. R., and Colado, M. I. (2001). The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol. 134, 46-57.
49. Scearce-Levie, K., Viswanathan, S. S., and Hen, R. (1999). Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl)141, 154-161.
50. Schmidt, C. J. (1987). Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol.Exp. Ther. 240, 1-7.
51. Schmidt, C. J., Black, C. K., and Taylor, V. L. (1990). Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur. J. Pharmacol. 181, 59-70.
52. Schuldiner, S., Steiner-Mordoch, S., Yelin, R., Wall, S. C., and Rudnick, G. (1993). Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44, 1227-1231.
53. Shioda, K., Nisijima, K., Yoshino, T., Kuboshima, K., Iwamura, T., Yui, K., and Kato, S. (2008). Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 29, 1030-1036.
54. Staal, R. G., and Sonsalla, P. K. (2000). Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther. 293, 336-342.
55. Taylor, T. N., Alter, S. P., Wang, M., Goldstein, D. S., and Miller, G.W. (2014). Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76(Pt A), 97-105.
56. Taylor, T. N., Caudle, W. M., and Miller, G. W. (2011). VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011, 124165.
57. Teng, L., Crooks, P. A., and Dwoskin, L. P. (1998). Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 71, 258-265.
58. Vergo, S., Johansen, J. L., Leist, M., and Lotharius, J. (2007). Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 1185, 18-32.
59. Walker, Q. D., Williams, C. N., Jotwani, R. P., Waller, S. T., Francis, R., and Kuhn, C. M. (2007). Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology (Berl) 189, 435-445.
60. Wang, Y. M., Gainetdinov, R. R., Fumagalli, F., Xu, F., Jones, S. R., Bock, C. B., Miller, G. W., Wightman, R. M., and Caron, M. G. (1997). Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285-1296.
61. Xie, T., Tong, L., McLane, M. W., Hatzidimitriou, G., Yuan, J., McCann, U., and Ricaurte, G. (2006). Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31, 2639-2651.
62. Yeh, S. Y. (1999). N-tert-butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse 31, 169-177.
63. Yehuda, S., Rabinovitz, S., and Mostofsky, D. I. (1999). Treatment with a polyunsaturated fatty acid prevents deleterious effects of Ro4-1284. Eur. J. Pharmacol. 365, 27-34.